Items where Author is "Symonds, P"
![]() | Up a level |
COOK, K., XUE, W., SYMONDS, P., DANIELS, I., GIJON, M., BOOCOCK, D., COVENEY, C., MILES, A., SHAH, S., ATABANI, S., CHOUDHURY, R., VAGHELA, P., WESTON, D., METHERINGHAM, R., BRENTVILLE, V. and DURRANT, L., 2021. Homocitrullination of lysine residues mediated by myeloid derived suppressor cells in the tumour environment is a target for cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 9 (7): e001910.
BRENTVILLE, V.A., VANKEMMELBEKE, M., METHINGHAM, R.L., SYMONDS, P., COOK, K.W., URBANOWICZ, R.A., TSOLERIDIS, T., COLEMAN, C.M., CHANG, K.-C., SKINNER, A., DUBININA, E., DANIELS, I., POCKLEY, A.G., SHAH, S., DIXON, J.E., ADAMS, S.E., PASTON, S.J., DALY, J.M., BALL, J.K. and DURRANT, L.G., 2021. A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants. Cold Spring Harbor Laboratory. (Submitted)